Canadian Stroke Prevention Intervention Network Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT02387229
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

rivaroxaban (xarelto) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2